Galectin-3 (Gal-3) is recognized as a prognostic marker in several cancer types. Its involvement in tumor development and proliferation makes this lectin a promising target for early cancer diagnosis and anti-cancer therapies. Gal-3 recognizes poly-N-acetyllactosamine (LacNAc)-based carbohydrate motifs of glycoproteins and glycolipids with a high specificity for internal LacNAc epitopes. This study analyzes the mode and kinetics of binding of Gal-3 to a series of multivalent neo-glycoproteins presenting complex poly-LacNAc-based oligosaccharide ligands on a scaffold of bovine serum albumin. These neo-glycoproteins rank among the strongest Gal-3 ligands reported, with Kd reaching sub-nanomolar values as determined by surface plasmon resonance. Significant differences in the binding kinetics were observed within the ligand series, showing the tetrasaccharide capped with N,N'-diacetyllactosamine (LacdiNAc) as the strongest ligand of Gal-3 in this study. A molecular model of the Gal-3 carbohydrate recognition domain with docked oligosaccharide ligands is presented that shows the relations in the binding site at the molecular level. The neo-glycoproteins presented herein may be applied for selective recognition of Gal-3 both on the cell surface and in blood serum.

Department of Biochemistry and Microbiology University of Chemistry and Technology Prague Technická 3 16628 Prague 6 Czech Republic

Institute of Microbiology of the Czech Academy of Sciences Vídeňská 1083 14220 Prague Czech Republic

Laboratory for Biomaterials Institute for Biotechnology and Helmholtz Institute for Biomedical Engineering RWTH Aachen University Pauwelsstrasse 20 52074 Aachen Germany

Zobrazit více v PubMed

Hirabayashi J., Kasai K. The family of metazoan metal-independent β-galactoside-binding lectins: Structure, function and molecular evolution. Glycobiology. 1993;3:297–304. doi: 10.1093/glycob/3.4.297. PubMed DOI

Liu F.T., Rabinovich G.A. Galectins as modulators of tumour progression. Nat. Rev. Cancer. 2005;5:29–41. doi: 10.1038/nrc1527. PubMed DOI

Iurisci I., Cumashi A., Sherman A.A., Tsvetkov Y.E., Tinari N., Piccolo E. Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis. Anticancer Res. 2009;29:403–410. PubMed

Ebrahim A.H., Alalawi Z., Mirandola L., Rakhshanda R., Dahlbeck S., Nguyen D., Jenkins M., Grizzi F., Cobos E., Figueroa J.A., et al. Galectins in cancer: Carcinogenesis, diagnosis and therapy. Ann. Transl. Med. 2014;2:88. doi: 10.3978/j.issn.2305-5839.2014.09.12. PubMed DOI PMC

Tellez-Sanz R., Garcia-Fuentes L., Vargas-Berenguel A. Human galectin-3 selective and high affinity inhibitors. Present state and future perspectives. Curr. Med. Chem. 2013;20:2979–2990. doi: 10.2174/09298673113209990163. PubMed DOI

Šimonová A., Kupper C.E., Böcker S., Müller A., Hofbauerová K., Pelantová H., Elling L., Křen V., Bojarová P. Chemo-enzymatic synthesis of LacdiNAc dimers of varying length as novel galectin ligands. J. Mol. Catal. B Enzym. 2014;101:47–55. doi: 10.1016/j.molcatb.2013.12.018. DOI

Laaf D., Bojarová P., Mikulová B., Pelantová H., Křen V., Elling L. Two-step enzymatic synthesis of β-d-N-acetylgalactosamine-(1→4)-d-N-acetylglucosamine (LacdiNAc) chitooligomers for deciphering galectin binding behavior. Adv. Synth. Catal. 2017;359:2101–2108. doi: 10.1002/adsc.201700331. DOI

Breloy I., Söte S., Ottis P., Bonar D., Grahn A., Hanisch F.-G. O-Linked LacdiNAc-modified glycans in extracellular matrix glycoproteins are specifically phosphorylated at the subterminal GlcNAc. J. Biol. Chem. 2012;287:18275–18286. doi: 10.1074/jbc.M111.280297. PubMed DOI PMC

Jin C., Kenny D.T., Skoog E.C., Padra M., Adamczyk B., Vitizeva V., Thorell A., Venkatakrishnan V., Lindén S.K., Karlsson N.G. Structural diversity of human gastric mucin glycans. Mol. Cell. Proteom. 2017;16:743–758. doi: 10.1074/mcp.M117.067983. PubMed DOI

Hirano K., Matsuda A., Shirai T., Furukawa K. Expression of LacdiNAc groups on N-glycans among human tumors is complex. Biomed. Res. Int. 2014;2014:981627. doi: 10.1155/2014/981627. PubMed DOI PMC

Haji-Ghassemi O., Gilbert M., Spence J., Schur M.J., Parker M.J., Jenkins M.L., Burke J.E., van Faassen H., Young N.M., Evans S.V. Molecular basis for recognition of the cancer glycobiomarker, LacdiNAc (GalNAc[β1→4]GlcNAc), by Wisteria floribunda agglutinin. J. Biol. Chem. 2016;291:24085–24095. doi: 10.1074/jbc.M116.750463. PubMed DOI PMC

Anugraham M., Jacob F., Everest-Dass A.V., Schoetzau A., Nixdorf S., Hacker N., Fink D., Heinzelmann-Schwarz V., Packer N.H. Tissue glycomics distinguish tumour sites in women with advanced serous adenocarcinoma. Mol. Oncol. 2017;11:1595–1615. doi: 10.1002/1878-0261.12134. PubMed DOI PMC

Wuhrer M., Koeleman C.A.M., Deelder A.M., Hokke C.H. Repeats of LacdiNAc and fucosylated LacdiNAc on N-glycans of the human parasite Schistosoma mansoni. FEBS J. 2006;273:347–361. doi: 10.1111/j.1742-4658.2005.05068.x. PubMed DOI

Hanzawa K., Suzuki N., Natsuka S. Structures and developmental alterations of N-glycans of zebrafish embryos. Glycobiology. 2017;27:228–245. doi: 10.1093/glycob/cww124. PubMed DOI

Böcker S., Laaf D., Elling L. Galectin binding to neo-glycoproteins: LacDiNAc conjugated BSA as ligand for human galectin-3. Biomolecules. 2015;5:1671–1696. doi: 10.3390/biom5031671. PubMed DOI PMC

Ahmed H., AlSadek D.M. Galectin-3 as a potential target to prevent cancer metastasis. Clin. Med. Insights Oncol. 2015;25:113–121. doi: 10.4137/CMO.S29462. PubMed DOI PMC

Collins P.M., Bum-Erdene K., Yu X., Blanchard H. Galectin-3 interactions with glycosphingolipids. J. Mol. Biol. 2014;426:1439–1451. doi: 10.1016/j.jmb.2013.12.004. PubMed DOI

Leffler H., Carlsson S., Hedlund M., Qian Y., Poirier F. Introduction to galectins. Glycoconj. J. 2004;19:433–440. doi: 10.1023/B:GLYC.0000014072.34840.04. PubMed DOI

Hsieh T.-J., Lin H.-Y., Tu Z., Lin T.-C., Wu S.-C., Tseng Y.-Y., Liu F.-T., Hsu S.-T.D., Lin C.-H. Dual thio-digalactoside-binding modes of human galectins as the structural basis for the design of potent and selective inhibitors. Sci. Rep. 2016;6:29457. doi: 10.1038/srep29457. PubMed DOI PMC

Rapoport E.M., Kurmyshkina O.V., Bovin N.V. Mammalian galectins: Structure, carbohydrate specificity, and functions. Biochemistry. 2008;73:393–405. doi: 10.1134/S0006297908040032. PubMed DOI

Morris S., Ahmad N., André S., Kaltner H., Gabius H.-J., Brenowitz M., Brewer F. Quaternary solution structures of galectins-1, -3, and -7. Glycobiology. 2004;14:293–300. doi: 10.1093/glycob/cwh029. PubMed DOI

Nieminen J., Kuno A., Hirabayashi J., Sato S. Visualization of galectin-3 oligomerization on the surface of neutrophils and endothelial cells using fluorescence resonance energy transfer. J. Biol. Chem. 2007;282:1374–1383. doi: 10.1074/jbc.M604506200. PubMed DOI

Massa S.M., Cooper D.N.W., Leffler H., Barondes S.H. L-29, an endogenous lectin, binds to glycoconjugate ligands with positive cooperativity. Biochemistry. 1993;32:260–267. doi: 10.1021/bi00052a033. PubMed DOI

Lepur A., Salomonsson E., Nilsson U.J., Leffler H. Ligand induced galectin-3 protein self-association. J. Biol. Chem. 2012;287:21751–21756. doi: 10.1074/jbc.C112.358002. PubMed DOI PMC

Ahmad N., Gabius H.J., André S., Kaltner H., Sabesan S., Roy R., Liu B., Macaluso F., Brewer C.F. Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J. Biol. Chem. 2004;279:10841–10847. doi: 10.1074/jbc.M312834200. PubMed DOI

Halimi H., Rigato A., Byrne D., Ferracci G., Sebban-Kreuzer C., ElAntak L., Guerlesquin F. Glycan dependence of galectin-3 self-association properties. PLoS ONE. 2014;9:e111836. doi: 10.1371/journal.pone.0111836. PubMed DOI PMC

Laaf D., Bojarová P., Pelantová H., Křen V., Elling L. Tailored multivalent neo-glycoproteins: Synthesis, evaluation, and application of a library of galectin-3-binding glycan ligands. Bioconjug. Chem. 2017;28:2832–2840. doi: 10.1021/acs.bioconjchem.7b00520. PubMed DOI

Lundquist J.J., Toone E.J. The cluster glycoside effect. Chem. Rev. 2002;102:555–578. doi: 10.1021/cr000418f. PubMed DOI

Wang H., Huang W., Orwenyo J., Banerjee A., Vasta G.R., Wang L.-X. Design and synthesis of glycoprotein-based multivalent glyco-ligands for influenza hemagglutinin and human galectin-3. Bioorg. Med. Chem. 2013;21:2037–2044. doi: 10.1016/j.bmc.2013.01.028. PubMed DOI PMC

Böcker S., Elling L. Biotinylated N-acetyllactosamine- and N,N-diacetyllactosamine-based oligosaccharides as novel ligands for human galectin-3. Bioengineering. 2017;4:31. doi: 10.3390/bioengineering4020031. PubMed DOI PMC

Dam T.K., Gabius H.J., André S., Kaltner H., Lensch M., Brewer C.F. Galectins bind to the multivalent glycoprotein asialofetuin with enhanced affinities and a gradient of decreasing binding constants. Biochemistry. 2005;44:12564–12571. doi: 10.1021/bi051144z. PubMed DOI

Abraham M.J., Murtola T., Schulz R., Páll S., Smith J.C., Hess B., Lindahl E. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1:19–25. doi: 10.1016/j.softx.2015.06.001. DOI

Lindorff-Larsen K., Piana S., Palmo K., Maragakis P., Klepeis J.L., O’Dror R., Shaw D.E. Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins. 2010;78:1950–1958. doi: 10.1002/prot.22711. PubMed DOI PMC

Kirschner K.N., Yongye A.B., Tschampel S.M., Daniels C.R., Foley B.L., Woods R.J. GLYCAM06: A generalizable Biomolecular force field. Carbohydrates. J. Comput. Chem. 2008;29:622–655. doi: 10.1002/jcc.20820. PubMed DOI PMC

Sousa da Silva A.W., Vranken W.F. ACPYPE—AnteChamber PYthon Parser interfacE. BMC Res. Notes. 2012;5:367. doi: 10.1186/1756-0500-5-367. PubMed DOI PMC

Korb O., Stützle T., Exner T.E. Empirical scoring functions for advanced protein-ligand docking with PLANTS. J. Chem. Inf. Model. 2009;49:84–96. doi: 10.1021/ci800298z. PubMed DOI

Saraboji K., Hakansson M., Genheden S., Diehl C., Qvist J., Weininger U., Nilsson U.J., Leffler H., Ryde U., Akke M., et al. The carbohydrate-binding site in galectin-3 is pre-organized to recognize a sugar-like framework of oxygens: Ultra-high resolution structures and water dynamics. Biochemistry. 2012;51:296–306. doi: 10.1021/bi201459p. PubMed DOI PMC

Blanchard H., Yu X., Collins P.M., Bum-Erdene K. Galectin-3 inhibitors: A patent review (2008–present) Expert Opin. Ther. Pat. 2014;24:1053–1065. doi: 10.1517/13543776.2014.947961. PubMed DOI

Öberg C.T., Leffler H., Nilsson U.J. Inhibition of galectins with small molecules. CHIMIA Int. J. Chem. 2011;65:18–23. doi: 10.2533/chimia.2011.18. PubMed DOI

Laaf D., Steffens H., Pelantová H., Bojarová P., Křen V., Elling L. Chemo-enzymatic synthesis of branched N-acetyllactosamine glycan oligomers for galectin-3 inhibition. Adv. Synth. Catal. 2017;359:4015–4024. doi: 10.1002/adsc.201700969. DOI

Kamili N.A., Arthur C.M., Gerner-Smidt C., Tafesse E., Blenda A., Dias-Baruffi M., Stowell S.R. Key regulators of galectin–glycan interactions. Proteomics. 2016;16:3111–3125. doi: 10.1002/pmic.201600116. PubMed DOI PMC

Stowell S.R., Arthur C.M., Mehta P., Slanina K.A., Blixt O., Leffler H., Smith D.F., Cummings R.D. Galectin-1, -2, and -3 exhibit differential recognition of sialylated glycans and blood group antigens. J. Biol. Chem. 2008;283:10109–10123. doi: 10.1074/jbc.M709545200. PubMed DOI PMC

Barboni E.A.M., Bawumia S., Colin Hughes R. Kinetic measurements of binding of galectin 3 to a laminin substratum. Glycoconjug. J. 1999;16:365–373. doi: 10.1023/A:1007004330048. PubMed DOI

Jin F., Chammas R., Engel J., Reinhold V. Structure and function of laminin 1 glycans; glycan profiling. Glycobiology. 1995;5:157–158. doi: 10.1093/glycob/5.2.157. PubMed DOI

Yoshioka K., Sato Y., Murakami T., Tanaka M., Niwa O. One-step detection of galectins on hybrid monolayer surface with protruding lactoside. Anal. Chem. 2010;82:1175–1178. doi: 10.1021/ac9022346. PubMed DOI

Javier Muñoz F., Ignacio Santos J., Ardá A., André S., Gabius H.-J., Sinisterra J.V., Jiménez-Barbero J., Hernáiz M.J. Binding studies of adhesion/growth-regulatory galectins with glycoconjugates monitored by surface plasmon resonance and NMR spectroscopy. Org. Biomol. Chem. 2010;8:2986–2992. doi: 10.1039/b927139b. PubMed DOI

Sauerzapfe B., Namdjou D.J., Schumacher T., Linden N., Křenek K., Křen V., Elling L. Characterization of recombinant fusion constructs of human beta 1,4-galactosyltransferase 1 and the lipase pre-propeptide from Staphylococcus hyicus. J. Mol. Catal. B Enzym. 2008;50:128–140. doi: 10.1016/j.molcatb.2007.09.009. DOI

Kupper C.E., Rosencrantz R.R., Henssen B., Pelantová H., Thönes S., Drozdová A., Křen V., Elling L. Chemo-enzymatic modification of poly-N-acetyllactosamine (LacNAc) oligomers and N,N-diacetyllactosamine (LacDINAc) based on galactose oxidase treatment. Beilstein J. Org. Chem. 2012;8:712–725. doi: 10.3762/bjoc.8.80. PubMed DOI PMC

Fischöder T., Laaf D., Dey C., Elling L. Enzymatic synthesis of N-acetyllactosamine (LacNAc) type 1 oligomers and characterization as multivalent galectin ligands. Molecules. 2017;22:1320. doi: 10.3390/molecules22081320. PubMed DOI PMC

Sauerzapfe B., Křenek K., Schmiedel J., Wakarchuk W.W., Pelantová H., Křen V., Elling L. Chemo-enzymatic synthesis of poly-N-acetyllactosamine (poly-LacNAc) structures and their characterization for CGL2-galectin-mediated binding of ECM glycoproteins to biomaterial surfaces. Glycoconj. J. 2009;26:141–159. doi: 10.1007/s10719-008-9172-2. PubMed DOI

Rech C., Rosencrantz R.R., Křenek K., Pelantová H., Bojarová P., Römer C.E., Hanisch F.G., Křen V., Elling L. Combinatorial one-pot synthesis of poly-N-acetyllactosamine oligosaccharides with Leloir-glycosyltransferases. Adv. Synth. Catal. 2011;353:2492–2500. doi: 10.1002/adsc.201100375. DOI

Bojarová P., Chytil P., Mikulová B., Bumba L., Konefał R., Pelantová H., Krejzová J., Slámová K., Petrásková L., Kotrchová L., et al. Glycan-decorated HPMA copolymers as high-affinity lectin ligands. Polym. Chem. 2017;8:2647–2658. doi: 10.1039/C7PY00271H. DOI

Essmann U., Perera L., Berkowitz M.L., Darden T., Lee H., Pedersen L.G. A smooth particle mesh Ewald method. J. Chem. Phys. 1995;103:8577–8593. doi: 10.1063/1.470117. DOI

Bussi G., Donadio D., Parrinello M. Canonical sampling through velocity-rescaling. J. Chem. Phys. 2007;126:014101. doi: 10.1063/1.2408420. PubMed DOI

Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., Ferrin T.E. UCSF Chimera—A visualization system for exploratory research and analysis. J. Comput. Chem. 2004;25:1605–1612. doi: 10.1002/jcc.20084. PubMed DOI

Hansson T., Marelius J., Åqvist J. Ligand binding affinity prediction by linear interaction energy methods. J. Comput. Aided Mol. Des. 1998;12:27–35. doi: 10.1023/A:1007930623000. PubMed DOI

Human Milk Oligosaccharides Multivalently Presented on Defined Synthetic Neo-Glycoproteins Are Nanomolar Ligands of Tandem-Repeat Galectins

Selective Glycopolymer Inhibitors of Galectin-3: Supportive Anti-Cancer Agents Protecting Monocytes and Preserving Interferon-Gamma Function

Glycopolymer Inhibitors of Galectin-3 Suppress the Markers of Tissue Remodeling in Pulmonary Hypertension

Lactose-Functionalized Carbosilane Glycodendrimers Are Highly Potent Multivalent Ligands for Galectin-9 Binding: Increased Glycan Affinity to Galectins Correlates with Aggregation Behavior

Oligosaccharide Ligands of Galectin-4 and Its Subunits: Multivalency Scores Highly

Engineered Glycosidases for the Synthesis of Analogs of Human Milk Oligosaccharides

Cross-Linking Effects Dictate the Preference of Galectins to Bind LacNAc-Decorated HPMA Copolymers

Interaction between Galectin-3 and Integrins Mediates Cell-Matrix Adhesion in Endothelial Cells and Mesenchymal Stem Cells

The β-N-Acetylhexosaminidase in the Synthesis of Bioactive Glycans: Protein and Reaction Engineering

Biocompatible glyconanomaterials based on HPMA-copolymer for specific targeting of galectin-3